Scilex Holding Company announced that it has filed a New Drug Submission (NDS) to Health Canada?s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the approval of ELYXYB® for acute treatment of migraine with or without aura in Canada.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8 USD | -0.61% | -12.79% | -60.78% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-60.78% | 97.49M | |
+9.85% | 72.5B | |
+13.69% | 9.11B | |
-12.85% | 5.07B | |
+60.16% | 5.01B | |
+1.60% | 3.85B | |
-19.20% | 2.46B | |
+18.65% | 2.44B | |
+24.62% | 2.27B | |
-27.46% | 2.26B |
- Stock Market
- Equities
- SCLX Stock
- News Scilex Holding Company
- Scilex Holding Company Announces Filing of New Drug Submission to Health Canada's Pharmaceutical Drugs Director, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada